Fortis Therapeutics, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: La Jolla CA United States (2016)

Organization Overview

First Clinical Trial
2018
NCT03575819
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Fortis Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

enzalutamide (xtandi) (1 trial)

for46 (3 trials)

Drugs in Phase 1 Trials (2)

64cu-dota-daratumumab (1 trial)

ys5 antibody (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Myeloma (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Prostatic Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 4